Tae Min Kim
Seoul National University Hospital · Seoul National University Hospital, Seoul, South Korea
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Tae Min Kim as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 00:35 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT05253118 · Relapsed or Refractory Primary Diffuse Large B-cell Lymphoma (DLBCL) of the Central Nervous System (CNS)Seoul National University Hospital · active not recruiting · DLBCL · principal investigator
- N/ANCT03969823 · Whole Genomic Landscape of Advanced EGFR-mutant NSCLCSeoul National University Hospital · active not recruiting · Locally Advanced or Metastatic NSCLC · principal investigator
- Ph2NCT03578198 · Rituximab Plus MG4101 Indolent CD20-positive Non-Hodgkin Lymphoma (NHL)Seoul National University Hospital · terminated · CD20-positive Non-Hodgkin Lymphoma · principal investigator
- Ph2NCT03414814 · Osimertinib for NSCLC With EGFR Exon 20 Insertion MutationSeoul National University Hospital · completed · Locally Advanced or Metastatic NSCLC · principal investigator
- Ph2NCT02388490 · Brentuximab Vedotin in Patients With Relapsed or Refractory EBV-and CD30-positive LymphomasSeoul National University Hospital · completed · Relapsed or Refractory EBV-and CD30-positive Lymphomas · principal investigator
- Ph2NCT01847235 · Temozolomide in Relapsed or Advanced Anaplastic Oligodendroglioma and Oligoastrocytoma: Single-arm, Phase II TrialSeoul National University Hospital · completed · Anaplastic Oligodendroglioma, Anaplastic Oligoastrocytoma · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-12 00:35 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 39 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- The epigenetic mechanism of enhancer RNA in behavioral plasticityR01NS085418 · NINDS · UT SOUTHWESTERN MEDICAL CENTER · fiscal years 2013 to 2017 · $347,813 awarded in 2017Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 00:35 UTC. The ranking covers the 200 most relevant of 107 PubMed records, and a shared surname and initials can bring in a namesake. All 107 on PubMed
- Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma.N Engl J Med · 20171,847 citationsRCR 59.7
- 918 citationsRCR 31.5
- 815 citationsRCR 33.3
- Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial.Lancet Oncol · 2016699 citationsRCR 20.7
- Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma.J Clin Oncol · 2020655 citationsRCR 30.2
- Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial.J Clin Oncol · 2023529 citationsRCR 47.7
- 451 citationsRCR 14.0
- Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial.Lancet Oncol · 2016361 citationsRCR 10.4
- Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study.J Clin Oncol · 2020338 citationsRCR 14.5
- 336 citationsRCR 9.1